Multiple antigenic peptide assay for detection of hiv or siv type retroviruses

Abstract

A method for detecting at least one antibody directed against at least one primate immunodeficiency virus in a biological sample that includes contacting a biological sample with (i) at least one detection multiple antigenic peptide comprising a portion of an immunodominant region of a transmembrane protein of a primate immunodeficiency virus and (ii) at least one differentiation multiple antigenic peptide comprising a portion of a V3-loop of an envelope protein of a primate immunodeficiency virus. Also disclosed is an enzyme immunoassay that includes a first substrate to which are bound at least one of the detection multiple antigenic peptides and a second substrate to which are bound at least one of the differentiation multiple antigenic peptides.

Description

CROSS REFERENCE TO RELATED APPLICATION [0001] This application claims the benefit of U.S. Provisional Patent Application No. 60 / 462,071 filed Apr. 11, 2003, which is incorporated herein by reference.FIELD [0002] This invention concerns assays for the detection of primate immunodeficiency viruses. BACKGROUND [0003] Human immunodeficiency virus (HIV) is subdivided into 2 types, HIV-1 and HIV-2, both of which are believed to be the result of separate zoonotic transmissions on at least eight different occasions (Hahn et al., Science 287:607-17, 2000; Sharp et al., Philos Trans R Soc Lond B Biol Sci 356:867-6, 2001) from chimpanzees and sooty mangabeys, respectively (Huet et al., Nature 345:356-359, 1990; Gao et al., Nature 397:436441, 1999; Hirsch et al., Nature 339:389-392, 1989). While the origin of HIV-1 from chimpanzees is mainly supported by the phylogenetic clustering of HIV-1 and SIVcpz, substantial evidence supports the zoonotic origin of HIV-2, including similarity in the viral...

AI Technical Summary

Benefits of technology

"The patent describes a method for detecting a primate immunodeficiency virus (PIV) infection by analyzing a biological sample, such as a serum sample, to detect the presence of anti-PIV antibodies. The method involves contacting the sample with two different peptides, one from the IDR region of the transmembrane envelope protein of PIV and another from the V3-loop of the envelope protein. The resulting immune complex with the peptides is detected, indicating infection with PIV. The method can be performed using an enzyme immunoassay with different detection and differentiation peptides. Diagnostic kits for detecting PIV infections are also described. The technical effect of this patent is a reliable and accurate method for detecting PIV infections in biological samples."

Problems solved by technology

This increasing human exposure to the plethora of SIVs prevalent in different species of wild primates may lead, or has already led, to additional transmissions of SIVs with the potential to cause new epidemics.

Unfortunately, new zoonotic transmissions may easily go undetected because of the lack of SIV-specific tests.

There is no commercially available test specifically designed for detecting all known SIVs.

Images